NASDAQ · Biotechnology

Eyenovia, Inc. (EYEN) Stock

$7.56 +3.99% NASDAQ: EYEN Healthcare

Eyenovia, Inc., a New York-based company established in 2014 (originally incorporated as PGP Holdings V, Inc.), functions as a clinical-stage pharmaceutical firm specializing in ophthalmology. The company utilizes its exclusive microdose array print platform technology and the Optejet branded targeted ocular delivery system to formulate innovative eye treatments.

Valuation

MetricValue
Price$7.56
Market Cap$38.59M
P/E Ratio-1.14
P/B Ratio1.37
P/S Ratio37.01
EPS (TTM)$-9.40
52-Week High$124.80
52-Week Low$0.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-109.76%
ROA-86.54%
ROCE-32.00%
Gross Margin-1900.00%
Operating Margin-1900.00%
Net Margin-4500.00%
Debt/Equity0.16
Current Ratio1.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$14.0M$0$0$0$1.0M
Operating Profit$-13.0M$-27.0M$-25.0M$-49.0M$-19.0M
Net Profit$-13.0M$-28.0M$-27.0M$-50.0M$-45.0M
EPS$-39.20$-66.59$-53.15$-59.81$-9.40
Op Margin-92.2%—-670885.8%-85004.6%-2333.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$31.0M$29.0M$4.0M$52.0M
Total Liabilities$11.0M$14.0M$20.0M$17.0M$11.0M
Cash$19.0M$23.0M$15.0M$2.0M$6.0M
Borrowings$7.0M$10.0M$16.0M$11.0M$9.0M

Latest News

Is Rollins (ROL) Fairly Valued On CFO Uncertainty And Slower Organic Growth? Simply Wall St. · Aug 8, 2026 Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Profit Guidance Why Valuation Still Looks Pricey Simply Wall St. · Aug 8, 2026 Invitation Homes (INVH) Q2 2026 Earnings Call Transcript Motley Fool · Aug 8, 2026 Lennox (LII) Q2 2026 Earnings Call Transcript Motley Fool · Aug 8, 2026 Acushnet Holdings (GOLF) Could Be 7% Undervalued As Earnings And Buyback Program Land Simply Wall St. · Aug 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-21.0M$-25.0M$-24.0M$-30.0M$-14.8B
Investing Cash Flow$-3.0M$-2.0M$-8.0M$0$-72.0B
Financing Cash Flow$2.0M$-1.0M$-1.0M$-3.0M$91.8B
Net Cash Flow$-1.0M$-4.0M$-8.0M$-13.0M$4.3B
Free Cash Flow$-22.0M$-26.0M$-28.0M$-30.0M$-14.8B

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.06
FCF Yield-38275.01%
Quick Ratio1.97
Interest Coverage-17.46
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CERCCerecor Inc. $2.93 -1.68% -0.53 $38.63M 0.00%
GRNAGreenLight Biosciences Holdings $0.30 -0.03% -0.24 $45.43M 0.00%
LIANYLianBio $0.07 -12.50% 1.56 $7.64M 6.14%
LUMOLumos Pharma, Inc. $4.34 +0.00% -1.04 $37.54M 0.00%
MGTAMagenta Therapeutics, Inc. $0.70 -7.74% -0.02 $42.44M 0.00%

About Eyenovia, Inc.

Eyenovia, Inc., a New York-based company established in 2014 (originally incorporated as PGP Holdings V, Inc.), functions as a clinical-stage pharmaceutical firm specializing in ophthalmology. The company utilizes its exclusive microdose array print platform technology and the Optejet branded targeted ocular delivery system to formulate innovative eye treatments. Its primary focus for research and development lies in addressing progressive myopia (nearsightedness), age-related near vision impairment (presbyopia), and pharmacologically induced pupil dilation for eye examinations. Eyenovia's developmental pipeline includes several advanced candidates, all currently undergoing Phase III clinical trials: MicroLine: Designed to enhance near vision for individuals with presbyopia. MicroPine: Aimed at slowing the progression of nearsightedness in pediatric patients. MydCombi: A microdose fixed-combination treatment intended for pharmaceutical mydriasis. Furthermore, Eyenovia has forged strategic alliances for product commercialization. It maintains a licensing agreement with Bausch Health Ireland Limited for the development and commercialization of MicroPine across the United States and Canada. Additionally, an agreement with Arctic Vision (Hong Kong) Limited covers the development and commercialization of both MicroPine and MicroLine in the markets of China and South Korea.

Eyenovia, Inc. is headquartered in US.

Eyenovia, Inc. (EYEN) stock trades at $7.56 with a market capitalization of $38.59M. The stock is valued at a price-to-earnings (P/E) ratio of -1.14, price-to-book of 1.37, price-to-sales of 37.01. Over the past 52 weeks the stock has ranged between $0.85 and $124.80, and currently trades 93.9% below its 52-week high.

On profitability, Eyenovia, Inc. generates a return on equity (ROE) of -109.76%, return on capital employed of -32.00%, an operating margin of -1900.00%, a net profit margin of -4500.00%.

Official website: www.eyenovia.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides